Evommune, Inc. (EVMN) stock

EVMNNYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30

$7.63−0.39 (-4.86%)

Close on Nov 13, 2026Market cap $276.91MP/E –Yield –

Evommune EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Evommune has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is EVMN.

Revenue growth-100.0% · median 320.4%

Advertisement
300 × 250

See a number that looks wrong?